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Doubly robust goodness-of-fit test of coarse structural
nested mean models with application to initiating
combination antiretroviral treatment in HIV-positive
patients
Shu Yang and Judith J. Lok
Abstract
Coarse structural nested mean models provide a useful tool to estimate treatment
effects from longitudinal observational data with time-dependent confounders. However
there is no existing guidance to specify the treatment effect model, and model misspe-
cification can lead to biased estimators, preventing valid inference. To test whether the
treatment effect model matches the data well, we derive a goodness-of-fit test procedure
based on overidentification restrictions tests. We show that our test statistic is doubly-
robust in the sense that with a correct treatment effect model, the test statistic has the
correct level if either the treatment initiation model or a nuisance regression outcome
model is correctly specified. In a simulation study we show the test procedure has
correct type-I error and is powerful to detect model misspecification. In addition, we
apply the test procedure to study how the timing of combination antiretroviral treat-
ment initiation after infection predicts the one year treatment effect in HIV-positive
patients with acute and early infection.
Keywords and phrases: Causal inference; Censoring; Doubly robust; Estimating
Equation; Goodness-of-fit test; HIV/AIDs; Longitudinal observational study; Overiden-
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tification restrictions test.
1 Introduction
The gold standard for evaluating effects of interventions are randomized controlled trials.
However, they are not always available; for example, for evaluating a treatment strategy for
HIV-positive patients, a randomized controlled trial would force patients to take the treat-
ment or to be off the treatment regardless of their health status. Observational studies are
useful in these settings. In observational studies, there often is time-dependent confounding
by indication: some covariates are predictors of both the subsequent treatment and outcome,
and are also affected by the past treatment history. Then, standard methods adjusting for
the covariates history are fallible and can lead to bias (Robins et al., 1992; Robins, 2000;
Robins et al. 2000).
Coarse structural nested mean models (Robins, 1998a) provide a useful tool to estim-
ate treatment effects from longitudinal observational data. Lok and DeGruttola (2012) de-
veloped a time-dependent version of coarse structural nested mean models and applied it to
investigate the impact of the timing of combination antiretroviral treatment initiation on the
effect of one year treatment in HIV-positive patients. Their semiparametric method leads
to an infinite number of unbiased estimating equations and a huge class of consistent and
asymptotically normal estimators. An optimal estimator can be derived within this class of
coarse structural nested mean models under well-specified models for the treatment effect,
treatment initiation, and a nuisance regression outcome model, in an unpublished 2014 tech-
nical report available from the second author. The key assumption lies in a well-specified
model for the treatment effect. However, no guidance exists on how to specify the treatment
effect model, and model misspecification may lead to biased estimators, preventing valid
inference.
The main contribution of this article is to derive a goodness-of-fit test statistic for testing
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correct specification of the treatment effect model. The key insight is that with a correctly-
specified treatment effect model we have more unbiased estimating equations than the num-
ber of parameters, which results in overidentification of the parameters. Overidentification
restrictions tests, also called Sargan tests or J-tests (Sargan, 1958 and Hansen, 1982), are
widely used in the econometric literature; they however seem to have been previously un-
noticed in the biostatistics literature. The standard overidentification restrictions test, given
by the minimized value of the generalized method of moments (Newey and McFadden, 1994;
Imbens et al., 1995) criterion function, has a chi-squared limiting distribution, with degrees
of freedom equal to the number of overidentification restrictions. In most situations, the
minimum of the generalized method of moments criterion is obtained by a continuous iter-
ative procedure to update the parameter estimates until convergence (Hansen et al., 1996).
Arellano and Bond (1991) showed the test statistic based on one-step estimates other than
the optimal generalized method of moments estimates is not robust and tends to over-reject
even in large samples. Our test procedure is different from the standard overidentification
restrictions tests in this regard. We do not obtain parameter estimates by minimizing an
objective function, but rather we obtain parameter estimates by solving the optimal estimat-
ing equations with the number of equations equal to the number of parameters. The overly
identified restrictions are only used for testing, not for estimation. This difference allows
us to greatly reduce the computation burden. Our simulation studies show that our test
statistic has correct size for large samples under the scenarios we considered. Another merit
of the overidentification restrictions test is that no bootstrap is needed to compute the test
statistic, which could be valuable with the large samples that are increasingly common.
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2 Motivating problem and basic setup
2.1 The motivating problem
Combination antiretroviral treatment is the standard initial treatment for HIV, and has
considerably reduced the morbidity and mortality in HIV-positive patients. In the HIV
literature, findings imply that there are key early events, during acute and early infection, in
the pathogenesis of HIV infection that determine the long-term pace of disease progression
(Hecht et al., 2006). However, there is no strong evidence to support when to start treatment
in patients in the acute and early stages of infection. It is important to understand the
effect of initiating treatment at different times during the course of HIV infection. This
investigation relies on an observational study, where we emulate a counterfactual experiment
using causal models.
2.2 The Acute Infection and Early Disease Research Program
The Acute Infection and Early Disease Research Program study is a multicenter, observa-
tional cohort study of 1762 HIV-positive patients diagnosed during acute and early infection
(Hecht et al., 2006). Dates of infection were estimated based on a stepwise algorithm that
uses clinical and laboratory data (Smith et al., 2006). We included patients with CD4 and
viral load measured within 12 months of the estimated date of infection, which resulted in
1696 patients. Let m denote the number of months between the estimated date of infection
and combination antiretroviral treatment initiation (m = 0, . . . , 11), where 0 indicates the
estimated date of infection. We are interested in evaluating the impact of m on the effect of
one year treatment.
2.3 Notation
Let Yk be the patient’s CD4 count at month k since the estimated date of infection (k =
0, . . . , K + 1 ≡ 24), and Lm be a vector of covariates measured at month m, including age,
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gender, race, injection drug use, CD4 count and viral load. Let Am be one if the patient was
on treatment at month m and zero otherwise. We assume that once treatment is started,
it is never discontinued. We use overbars to denote a variable history; for example, A¯m is
the treatment history until month m. Let T be the actual treatment initiation time. The
patients are assumed to be an independent sample from a larger population (Rubin, 1978),
and for notational simplicity we drop the subscript i for patients. To handle missingness,
for L, if this is missing at month m, Lm was coded as “missing”. For intermediate missing
outcomes, we imputed Yk by interpolation; if the outcome is missing just prior to onset of
treatment, we imputed Yk by carrying the last observation forward. Let X ≡ (A¯K , L¯K , Y¯K+1)
denote the patient’s full record. Until Section 6 we assume all patients are followed up until
month K + 1.
Let Y
(m)
k be the CD4 count at month k, possibly counterfactual, had the patient started
treatment at month m. Let Y
(∞)
k be the CD4 count at month k had the patient never started
treatment during the course of follow up. We assume the patient’s observed outcome Yk is
equal to the potential outcome Y
(m)
k for m equal to the actual treatment initiation time T ;
that is, if k > T , Yk = Y
(T )
k and if T ≥ k, Yk = Y (∞)k .
We assume the assumption of no unmeasured confounding (Robins et al., 1992):
Y
(∞)
k ∐ Am | L¯m, A¯m−1 (k = m+ 1, . . . , m+ 12), (1)
where ∐ denotes “is independent of” (Dawid, 1979). This assumption holds if L¯m contains
all prognostic factors for Y
(∞)
k that affect the treatment decision at month m. For example,
if patients with lower CD4 counts initiated treatment earlier, the assumption (1) would fail
to hold if L¯m does not include the history of the CD4 count.
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2.4 Coarse structural nested mean model
We model the treatment effect, comparing treatment starting at month m to never starting
among the subgroup of patients with covariate history l¯m and T = m, as
E{Y (m)k − Y (∞)k | L¯(∞)m = l¯m, T = m} = γkm,ψ(l¯m) (k = m, . . . ,m+ 12), (2)
where ψ is the parameter in the treatment effect model. From now on, we consider γkm,ψ(l¯m) =
(ψ1 + ψ2m)(k −m)1(m≤k), with (k −m) the duration of treatment from month m to month
k. We restrict the range of k from 12 to K + 1, whereby we avoid making extra modeling
assumptions beyond the necessary ones to estimate γm+12m (l¯m) in order to gain robustness.
Particularly, γm+12m,ψ (l¯m) quantifies the effect of one year treatment if HAART was initiated at
month m, among the subgroup of patients with covariate history l¯m. If outcome is the CD4
count and γm+12m,ψ (l¯m) > 0, the effect of one year treatment is beneficial. 12ψ1 quantifies the
effect of one year treatment if treatment was started at the estimated date of infection, and ψ2
quantifies the increase of the effect of treatment for each month of delay after the estimated
date of infection. Under this model, the treatment effect is homogeneous. In practice, the
treatment effect may vary among different groups; for example, male and female patients
may have different responses to the combination antiretroviral treatment. We can then
extend the model as γkm,ψ(l¯m) = (ψ1 + ψ2m+ ψ3gender)(k −m)1{m≤k}, where ψ3 quantifies
the magnitude and direction of the impact of gender.
For k = 12, . . . , K + 1, define H(k) = Yk − γkT (L¯T ). As proved in Robins et al. (1992),
Lok et al. (2004) and Lok and DeGruttola (2012), H(k) is mimicking a counterfactual out-
come Y
(∞)
k in the sense that for k = 12, . . . , K + 1 and m = k − 12, . . . , k − 1,
E{H(k) | L¯m, A¯m−1 = 0¯, Am} = E{Y (∞)k | L¯m, A¯m−1 = 0¯, Am}, (3)
since by subtracting from the observed Yk the average effect of treatment, we would obtain
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the quantity that mimics the outcome had the patient not been treated. The implication
of (3) and the assumption of no unmeasured confounding is that for k = 12, . . . , K + 1 and
m = k − 12, . . . , k − 1,
E{H(k) | L¯m, A¯m−1 = 0¯, Am} = E{H(k) | L¯m, A¯m−1 = 0¯}, (4)
which plays a key role for estimation.
2.5 The conditional probability of treatment initiation
We use a pooled logistic regression to model the probability of treatment initiation at
month m, conditional on the past history, pθ(m) ≡ P (Am = 1 | A¯m−1 = 0¯, L¯m; θ) =
1(A¯m−1=0¯)1visit(m)/[1 + exp{−θTf(L¯m)}], where 1visit(m) is an indicator of whether a visit
took place at month m, and f(L¯m) is some function of L¯m. Let Jtrt(θ)(X) denote the estim-
ating function for θ0.
2.6 The unbiased estimating equation and optimal estimation
Model (2) cannot be fit by standard regression methods because it involves potential out-
comes. However, one can get consistent estimates by constructing unbiased estimating
equations based on (4) (Lok and DeGruttola, 2012): for any measurable, bounded function
qkm : L¯m → Rp, k = 12, . . . , K + 1, m = k − 12, . . . , k − 1, let
G(ψ,θ,q)(X) ≡
K+1∑
k=12
k−1∑
m=k−12
qkm(L¯m)[Hψ(k)− E{Hψ(k)|L¯m, A¯m−1 = 0¯}]{Am − pθ(m)}.
We use empirical process notation throughout. We let P denote the probability measure
induced by X and let Pn denote the empirical measure induced by X1, ..., Xn. Given a
measurable function f : X 7→ R, we write Pnf(X) = n−1
∑n
i=1 f(Xi) and Pf(X) for the
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expectation under P . Then
Pn{ G(ψ,θ,q)(X)T Jtrt(θ) (X)T}T = 0 (5)
are the stacked unbiased estimating equations for both the parameter ψ and the (nuisance)
parameter θ. For simplicity, we will suppress the dependence of the estimating functions
on X; for example, PnG(ψ,θ,q) is shorthand for PnG(ψ,θ,q)(X). Sometimes, we also drop the
dependence on the parameters.
In theory, q can be chosen arbitrarily; however it largely influences the precision of the
resulting estimator. To derive the optimal estimating equation, and therefore the optimal
estimator, we assume that for k, s = 12, . . . , K + 1 and m with m = max(k − 12, s −
12), . . . ,min(k − 1, s− 1, K),
cov{H(k), H(s) | L¯m, A¯m−1 = 0¯, Am} ∐ Am | L¯m, A¯m−1. (6)
This assumption is a natural extension of (4). This would be true under Robins (1998b)’s
rank preservation assumption and (Y
(∞)
k , Y
(∞)
s )∐Am | L¯m, A¯m−1. However, the rank preser-
vation assumption is unlikely to hold in practice and the assumption (6) is weaker.
The optimal estimating equations, within the class of PnG(ψ,θ,q) indexed by q for any meas-
urable and bounded functions qkm, can be obtained by finding q
opt that satisfies E{∂/∂ψTG(ψ0,θ0,q)} =
E{G(ψ0,θ0,q)GT(ψ0,θ0,qopt)} for any q (Newey and McFadden, 1994). Then, under (6)
qoptm (L¯m)
T ≡ {var(Hm | L¯m, A¯m−1 = 0¯)}−1
×
{
E
(
∂
∂ψ
Hm | L¯m, A¯m−1 = 0¯, Am = 1
)
− E
(
∂
∂ψ
Hm | L¯m, A¯m = 0¯
)}
, (7)
where qoptm = (q
opt,l
m , . . . , q
opt,r
m ) with l = max(m + 1, 12) and r = min(m + 12, K + 1),
which are informed by the fact that m + 1 ≤ k ≤ m + 12 and 12 ≤ k ≤ K + 1;
Hm = {Hψ(l), . . . , Hψ(r)}T ; var(Hm | L¯m, A¯m−1 = 0¯) is a matrix with elements Γmks ≡
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cov{Hψ(k), Hψ(s) | L¯m, A¯m−1 = 0¯}; and E(∂/∂ψHm | L¯m, A¯m−1 = 0¯, Am = 1)−E(∂/∂ψHm |
L¯m, A¯m = 0¯) = (∆
l
m, . . . ,∆
r
m)
T with∆km ≡ E{∂/∂ψHψ(k) | L¯m, A¯m−1 = 0¯, Am}−E{∂/∂ψHψ(k) |
L¯m, A¯m−1 = 0¯}.
Remark 1 For the optimal estimating equations, defined by (5) and (7), we address two
issues. One issue is that E{Hψ(k) | L¯m, A¯m−1 = 0¯} and qopt depend on ψ. Following
Lok and DeGruttola (2012), we use a preliminary consistent estimate ψˆp to replace ψ0 in
E{Hψ(k) | L¯m, A¯m−1 = 0¯} and qopt. The rationale for this replacement is that the estimating
equations are unbiased for any fixed value of ψˆp when pθ(m) is correct. If γ
k
m,ψ is linear in
ψ, ∆km does not depend on ψ. One choice of ψˆp is the optimal estimator if q
k
m is only non-
zero for k = m + 12. Another issue is that ∆km and E{Hψ(k) | L¯m, A¯m−1 = 0¯}, even with
ψ in lieu of ψp, depend on the true unknown distribution. We will use parametric models
to approximate these quantities. Let E{Hψp(k) | L¯m, A¯m−1 = 0¯} be parametrized by ξ1;
for example Eξ1{Hψp(k) | L¯m, A¯m−1 = 0¯} is a linear regression model with covariates L¯m.
Likewise, let ∆km be parametrized by ξ2. Denote estimating functions for ξ1, ξ2 and ψp by
J1(ξ1,ψp), J2(ξ2) and Gp(ψp,ξ2). Since Gp depends on ∆
m+12
m , it is also a function of ξ2.
3 Asymptotic results of optimal estimators
We present the consistency and asymptotic normality result of the optimal estimator. These
results are the building blocks to derive the goodness-of-fit test statistic.
Theorem 1 (Consistency) Let G∗(ψ,ψp,ξ,θ) be optimal estimating functions
G∗(ψ,ψp,ξ,θ) =
K+1∑
k=12
k−1∑
m=k−12
qk,optm,ψp,ξ2(L¯m)[Hψ(k)−Eξ1{Hψp(k) | L¯m, A¯m−1 = 0¯}]{Am − pθ(m)},
and U(ψ,ψp,ξ,θ) = { G∗(ψ,ψp,ξ1,ξ2,θ) Gp(ψp,ξ2) J1(ξ1,ψp) J2(ξ2) Jtrt(θ)}T be a system of estim-
ating functions stacking all estimating functions together, where Gp, J1 and J2 are defined
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in Remark 1, and Jtrt is defined in (5). Let (ψˆ, ψˆp, ξˆ, θˆ) be the solution to estimating equa-
tions PnU(ψ,ψp,ξ,θ) = 0. The true parameter values are ψ0, ξ0 and θ0. Under the regularity
conditions (C1)–(C2) specified in the Supplementary Material, if the treatment effect model
γkm,ψ(L¯m) is well specified, and either Eξ1{Hψ(k)|L¯m, A¯m−1 = 0¯} or pθ(m) is well specified,
ψˆ − ψ0 → 0 in probability, as n→∞.
Theorem 2 (Asymptotic normality) Under the regularity conditions (C1)–(C5) specified
in the Supplementary Material, n1/2(ψˆ−ψ0)→ Np (0,Σψ) in distribution, as n→∞, where
p is the dimension of ψ0 and Σψ is the p×p upper left matrix in {P∂/∂(ψ, ψp, ξ, θ)U}−1P (U
UT ){P∂/∂(ψ, ψp, ξ, θ)U}−1T .
Remark 2 In the statistics literature, estimators solving unbiased estimating equations are
often called Z-estimators. The theory of consistency and asymptotic normality of Z-estimators
is well established, see for example Theorem 5.9 and Section 5.3 in Van der Vaart (2000).
We skip the detailed proof but explain the regularity conditions needed to guarantee the con-
sistency in the Supplementary Material. From Theorem 1, the functional form of γkm,ψ
must be correctly specified. In contrast, the estimator remains consistent for ψ if either
Eξ1{Hψ(k)|L¯m, A¯m−1 = 0¯} or pθ(m) is well specified, but not necessary both. The estim-
ator is doubly robust (Robins and Rotnitzky, 2001; Van der Laan and Robins, 2003). The
functional form of the nuisance models can be selected on the basis of the observed data, as
well as the literature and subject knowledge specific to the application setting. Later in this
article, we provide a more specific illustration in the context of our example.
4 Goodness-of-fit test
The consistency, asymptotic normality, and double robustness of estimators rely on a key
assumption, that is, the treatment effect model is well specified. Misspecification of the treat-
ment effect model causes bias in the parameter estimation and break down the asymptotic
results. We now develop tests for model specification based on overidentification restrictions
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tests. Conceptually, for a well specified model, a new set of unbiased estimating functions,
other than the optimal ones that are used for estimation, evaluated at the optimal estimat-
ors, should be asymptotically concentrated at zero. This asymptotic behavior leads to the
following theorem:
Theorem 3 (Goodness-of-Fit Test) Let the treatment effect model be γkm,ψ(l¯m) and Hψ(k) =
Yk−γkT,ψ(l¯T ). Choose a set of functions {q˜km(L¯m) ∈ Rν , k = 12, . . . , K+1, m = k−12, . . . , k−
1} that are different from the optimal choice qk,optm . Let
G˜(ψ,ψp,ξ,θ) =
K+1∑
k=12
k−1∑
m=k−12
q˜km,ξ2(L¯m)[Hψ(k)− Eξ1{Hψp(k) | L¯m, A¯m−1 = 0¯}]{Am − pθ(m)}.
Let (ψˆ, ψˆp, ξˆ, θˆ) be as in Theorem 1. The null hypothesis is H0: γ
k
m(l¯m) is well specified, and
either Eξ1{Hψ(k) | L¯m, A¯m−1 = 0¯} or pθ(m) is well specified. Under H0 and the regular-
ity conditions (C1)–(C10) specified in the Supplementary Material, the goodness-of-fit test
statistic
GOF = n{PnG˜(ψˆ,ψˆp,ξˆ,θˆ)}T Σˆ−1PnG˜(ψˆ,ψˆp,ξˆ,θˆ) → χ2(ν), (8)
in distribution, as n → ∞, where Σ is the variance of Φ(ψ0,ψ0,ξ0,θ0) with Φ(ψ0,ψ0,ξ0,θ0) the
asymptotic linear representation of G˜(ψˆ,ψˆp,ξˆ,θˆ), which is a linear combination of G
∗, G˜, Gp,
J1, J2 and Jtrt, defined in (6) in the Supplementary Material, and Σˆ is the sample variance
of Φ(ψˆ,ψˆp,ξˆ,θˆ).
We state the key steps in the proof, with details in the Supplementary Material. To
establish the asymptotic distribution of n1/2PnG˜(ψˆ,ψˆp,ξˆ,θˆ), and therefore that of GOF , a key
step is to linearise n1/2PnG˜(ψˆ,ψˆp,ξˆ,θˆ) as n
1/2PnΦ(ψ0,ψ0,ξ0,θ0) for some Φ, whereby we can apply
the typical central limit theorem. To do so, the Lipschitz condition (C7) implies the functions
G˜(ψ,ψp,ξ,θ) form a Donsker class. Using Lemma 19.24 of Van der Vaart (2000), we have
√
n(Pn − P )G˜(ψˆ,ψˆp,ξˆ,θˆ) =
√
n(Pn − P )G˜(ψ0,ψ0,ξ0,θ0) + op(1). (9)
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Next, we apply a Taylor expansion to PG˜(ψˆ,ψˆp,ξˆ,θˆ) on the left hand side of (9) and use the fact
that PG˜(ψ0,ψ0,ξ0,θ0) = 0 on the right hand side of (9). Finally, we can express Φ(ψ0,ψ0,ξ0,θ0),
the asymptotic linear representation of G˜(ψˆ,ψˆp,ξˆ,θˆ), to be a linear combination of G
∗, G˜, Gp,
J1, J2 and Jtrt.
Remark 3 (Double Robustness) The goodness-of-fit test statistic is doubly robust in the
sense that for (8) to hold we only require that either Eξ1{Hψ(k)|L¯m, A¯m−1 = 0¯} or pθ(m) is
well specified, not necessary for both. This property adds a protection from possible misspe-
cification of the nuisance models.
Remark 4 The standard overidentification restrictions test is minψ nPnV
T
(ψ){Σˆ(ψ)}−1PnV(ψ),
where V(ψ) ≡ ( G∗
(ψ,ψˆp,ξˆ1,ξˆ2,θˆ)
G˜(ψ,ψˆp,ξˆ,θˆ)
)T and Σ(ψ) is the asymptotic variance of PnV(ψ).
In most situations, the minimum is obtained by a continuous iterative procedure to update
the parameter estimates; that is, ψˆ(t+1) = argminψ nPnV
T
(ψ){Σˆ(ψˆ(t))}−1PnV(ψ) until conver-
gence (Hansen et al., 1996). Our test procedure does not need any iterative procedure, which
simplifies the calculation.
Remark 5 (Choosing q˜) Just like a naive choice of q in estimating equations may lead
to an estimator with large variance and thus useless inference, an arbitrary choice of q˜ may
lead to the goodness-of-fit test lacking of power. We propose the following procedure to choose
q˜, which is powerful in certain circumstances. Suppose we have two models to choose from
for the treatment effect. Let the null model be γ∗ψ, which is the treatment effect model we
are testing for, and the other model to be an alternative model γ˜ψ. We can derive ∆
∗, q∗opt,
∆˜, and q˜opt as in (7) with γ∗ψ and γ˜ψ. Note that q
∗opt is used for optimal estimation of the
parameters in the null model. Then, candidates for q˜ are ∆∗, ∆˜, q˜opt, or any subvector of
these that is not included in q∗opt. Our simulation study shows that the goodness-of-fit test
with q˜opt is most powerful among this set of candidates in detecting the alternative model.
12
5 Extension of goodness-of-fit test in the presence of cen-
soring
We use the Inverse-Probability-of-Censoring-Weighting technique (Robins et al., 1995; Hernán et al.,
2005; Lok and DeGruttola, 2012) to accommodate patients lost to follow-up. Let Cp = 0
indicate a patient remains in the study at month p. Following Lok and DeGruttola (2012),
we assume that censoring is missing at random; that is, (L¯, A¯) ∐ Ck+1 | L¯k, A¯k, C¯k = 0¯,
whereby we have P (Am = 1 | L¯m, A¯m−1 = 0¯, C¯m = 0¯) = P (Am = 1 | L¯m, A¯m−1 = 0¯), and
pθ(m) does not depend on censoring. Define the Inverse-Probability-of-Censoring-Weightingg
version of estimating functions G∗c and G˜c using weights W km,η = 1/{
∏k
p=m+1 Pη(Cp = 0 |
L¯p−1, A¯p−1, C¯p−1 = 0¯)}, see the Supplementary Material for details. In calculation of the
weights, we use a pooled logistic regression model to estimate Pη(Cp = 0 | L¯p−1, A¯p−1, C¯p−1 =
0¯). We assume the censoring model is well specified with estimating functions Jcen(η). Simil-
arly, we have the Inverse-Probability-of-Censoring-Weighting version of the estimating func-
tion for the preliminary estimator ψˆp, denoted by G
c
p. For the nuisance regression outcome
models, the regression was restricted to patients still in follow-up and use weighted regression
analysis with the censoring weights.
Define the goodness-of-fit test statistic as
GOF c = n{PnG˜c(ψˆ,ψˆp,ξˆ,θˆ,ηˆ)}
T (Σˆc)−1PnG˜
c
(ψˆ,ψˆp,ξˆ,θˆ,ηˆ)
,
where Σˆc is the sample variance of Φc
(ψˆ,ψˆp,ξˆ,θˆ,ηˆ)
, with Φc(ψ0,ψ0,ξ0,θ0,η0) the asymptotic linear
representation of G˜c
(ψˆ,ψˆp,ξˆ,θˆ,ηˆ)
, defined by (10) in the Supplementary Material. As proved
in the Supplementary Material, subject to regularity conditions, GOF c has an asymptotic
chi-squared distribution, with degrees of freedom dimension of G˜c.
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6 Simulations
The simulation designs were based on the Acute Infection and Early Disease Research Pro-
gram database, but we did not consider censoring. Following an unpublished 2014 tech-
nical report available from the second author, we first generated the CD4 count outcomes
Y
(∞)
k under no treatment, followed by a treatment initiation time T , and lastly the ob-
served outcomes Yk (k = 6, . . . , 30), as follows: (i) In each sample, 2 groups were sim-
ulated: injection drug users (10%) and patients who never used drugs (90%), and then
log Y
(∞)
6 ∼ N(6 · 0, 0 · 42) for injection drug users, and N(6 · 6, 0 · 52) for non injection drug
users. For k ≥ 6, Y (∞)k+1 = −10+Y (∞)k +ǫk+1, where ǫk ∼ N(0, σ2k) with σk = 52 ·375−1 ·625k
for k = 7, . . . , 19 and σk = 21 · 5 for k = 20, . . . , 30; (ii) T was generated by a logistic regres-
sion model logit{P (T = m | T ≥ m, L¯m)} = −2 · 4− 0 · 42injdrug− 0 · 0035Y (∞)m − 0 · 026m,
where injdrug is an indication of being an injection drug user; and (iii) Yk = Y
(∞)
k + γ
k
T (L¯T ).
We considered different models for γkm.
The performance of the test statistics was assessed by their ability (i) to confirm the
adequacy of a model that is correctly specified with the data-generating model (type-I error)
and (ii) to reject a misspecified model (power). The model under the null hypothesis H0
upon which the goodness-of-fit statistic is based, and the alternative hypothesis Ha were
specified as H0 : γ
k
m,ψ = (ψ1 + ψ2m)(k − m) versus Ha : γkm,ψ 6= (ψ1 + ψ2m)(k − m). Six
scenarios regarding the true treatment effect model, H0 and a parametric specification of Ha
were specified as follows:
Scenario (a): True: γkm,ψ = (25 − 0 · 7m)(k −m), H0 : γkm,ψ = (ψ1 + ψ2m)(k −m), and
Ha : γ
k
m,ψ = (ψ1 + ψ2m+ ψ3m
2)(k −m);
Scenario (b): True: γkm,ψ = (25−0·7m)(k−m), H0 : γkm,ψ = (ψ1+ψ2m+ψ3injdrug)(k−m),
and Ha : γ
k
m,ψ = (ψ1 + ψ2m+ ψ3m
2)(k −m);
Scenario (c): True: γkm,ψ = (35−1 ·1m+0 ·04m2)(k−m), H0 : γkm,ψ = (ψ1+ψ2m)(k−m),
and Ha : γ
k
m,ψ = (ψ1 + ψ2m+ ψ3m
2)(k −m);
Scenario (d): True: γkm,ψ = (35−1 ·1m+0 ·04k2)(k−m), H0 : γkm,ψ = (ψ1+ψ2m)(k−m),
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and Ha : γ
k
m,ψ = (ψ1 + ψ2m+ ψ3m
2)(k −m);
Scenario (e): True: γkm,ψ = (25−m+ 0 · 03m2)(k −m), H0 : γkm,ψ = (ψ1 + ψ2m)(k −m),
and Ha : γ
k
m,ψ = (ψ3 + ψ4m)(k −m)3/2;
Scenario (f): True: γkm,ψ = (10− 1 · 1m)(k −m)3/2, H0 : γkm,ψ = (ψ1 + ψ2m)(k −m), and
Ha : γ
k
m,ψ = (ψ3 + ψ4m)(k −m)3/2.
Specifically, in Scenarios (a) and (b), H0 is correctly specified. In Scenarios (c)–(f), H0
is misspecified with different degrees of departure from the true model. In Scenarios (c) and
(d), H0 is nested in the parametric specification of Ha. In Scenarios (e) and (f), H0 is not
nested in the parametric specification of Ha.
Type-I error and power were estimated by the frequency of rejecting H0 using 1, 000
simulated datasets. We considered the following choices of q˜: (i) q˜km ≡ 1, which is a naive
choice for comparison; (ii) q˜km = ∆˜
k
m; and (iii) q˜
k
m = q˜
opt,k
m . (ii) and (iii) were derived under
the parametric specification of Ha.
The optimal estimator was obtained by solving (5) with (7). In (5), the treatment
initiation model was fitted by a logistic regression model adjusting for Ym, injection drug use,
and month, restricted to patients and visits with A¯m−1 = 0¯. Thus, the treatment initiation
model was correctly specified. E{Hψp(k) | A¯m−1 = 0¯, L¯m} was fitted by a linear regression
model adjusting for CD4m and (k−m), restricted to patients and visits with A¯m−1 = 0¯. The
covariates were motivated by (3) and the data generating mechanism. The nuisance models
in qoptm are specified in the Supplementary Material for simplicity of presentation, which do
not affect the double robustness of the estimator.
In addition to the goodness-of-fit test statistic, we considered an elaborated-model-fitting-
and-testing approach, which combines the null model and the parametric specification of
the alternative model and tests the significance of the parameters corresponding to the
alternative model.
From Scenarios (a) and (b) in Table 1, where the treatment effect model under H0 is
correctly specified, the goodness-of-fit test procedure with all choices of q˜ controls type-
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I error for n = 1, 000 and n = 2, 000. This suggests that the chi-squared distribution
derived in this article provides an accurate approximation to the finite sample behavior of
the goodness-of-fit test statistic for these sample sizes.
From Scenarios (c)–(f), where the treatment effect model is not correctly specified, the
goodness-of-fit test procedure with the optimal q˜km derived under the parametric specification
of Ha is most powerful, and as the sample size increases, the power increases, confirming
the theoretical results. From Scenarios (c) and (d), the goodness-of-fit test procedure and
the elaborated-model-fitting-and-testing approach are comparable when testing nested mod-
els. In both scenarios, the goodness-of-fit test procedure is slightly more powerful than
the elaborated-model-fitting-and-testing approach for n = 500 and n = 1, 000, which is
not apparent for n = 2, 000. For Scenarios (e) and (f), the null treatment effect model is
not nested in the parametric specification of Ha. Under Scenario (e), the goodness-of-fit
test statistic with q˜opt,km shows more power than the elaborated-model-fitting-and-testing ap-
proach, likely because the elaborated-model-fitting-and-testing approach fits a larger model
and loses power. Under Scenario (f), the goodness-of-fit test statistic with q˜opt,k3m is slightly
more powerful than the elaborated-model-fitting-and-testing approach for n = 500, and both
approaches are powerful to reject the null model in other cases.
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Table 1: Type-I error estimates and power estimates (×100) for testing the null model
H0 by the proposed goodness-of-fit (GOF) test statistic with q˜ being 1, ∆˜, and q˜
opt, and
the Elaborated Model Fitting and Testing (EMFT) approach over 1, 000 simulations under
Scenarios (a)–(f)
Type-I error estimates in Scenario (a) Type-I error estimates in Scenario (b)
GOF EMFT GOF EMFT
n\q˜ 1 ∆˜km q˜
opt,k
m 1 ∆˜
k
3m q˜
opt,k
m
500 5 · 3 4 · 3 5 · 2 4 · 9 9 · 1 9 · 8 12 · 3 13 · 5
1000 4 · 5 5 · 7 5 · 6 5 · 4 5 · 3 4 · 4 5 · 4 5 · 7
2000 4 · 8 4 · 4 5 · 2 5 · 3 5 · 2 4 · 4 5 · 2 5 · 3
Power estimates in Scenario (c) Power estimates in Scenario (d)
GOF EMFT GOF EMFT
n\q˜ 1 ∆˜km q˜
opt,k
m 1 ∆˜
k
m q˜
opt,k
m
500 15 29 59 56 90 96 97 83
1000 28 55 89 84 100 100 100 97
2000 52 88 99 99 100 100 100 100
Power estimates in Scenario (e) Power estimates in Scenario (f)
GOF EMFT GOF EMFT
n\q˜ 1 ∆˜km q˜
opt,k
m 1 ∆˜
k
m q˜
opt,k
m
500 12 25 49 28 93 99 100 96
1000 24 53 73 54 100 100 100 100
2000 48 79 91 80 100 100 100 100
7 Application
We applied the proposed goodness-of-fit test to study how the timing of combination antiret-
roviral treatment initiation after infection predicts the effect of one year of treatment in HIV-
positive patients. We used the Acute Infection Early Disease Research Program database.
We started with a simple null model for the treatment effect, H0 : γ
k
m,ψ = (ψ1+ψ2m)(k−m),
and conducted directed alternative-model tests by testing whether possible effect modifi-
ers should be added into the model. In the HIV literature, it has been found that there
may be gender differences in immunologic response to combination antiretroviral treatment:
early studies suggested that clinical disease progression was more rapid in women than men
with combination antiretroviral treatment (Friedland et al., 1991; Bozzette et al., 1998); con-
versely, more recent studies have shown that women have better immunologic outcomes
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than men on treatment(Maman et al., 2012; Maskew et al., 2013). It has also been shown
that older age is associated with a poorer CD4 count increase with combination antiret-
roviral treatment (Maman et al., 2012; Maskew et al., 2013). Injection drug use has been
found to be associated with reduced effectiveness of combination antiretroviral treatment
(Poundstone et al., 2001). As suggested by the literature, we considered tests directed at 3
variables: gender, age, and injection drug use. For the test directed at a certain variable Z,
we calculated the goodness-of-fit test statistic with q˜ being the optimal form derived from
the parametric specification of the alternative model γ˜km,ψ = (ψ1+ψ2m+ψ3Z)(k−m)1(k>m).
The nuisance models were specified on the basis of the observed data, the clinical liter-
ature, and subject knowledge. For the censoring model, we used a logistic regression model
adjusting for square root of current CD4 count (CD41/2m ), current log viral load, gender, age,
injection drug use (injdrug), month, squared month, and whether a patient was treated, as
discussed in Krishnan et al. (2011) and Lok et al. (2010). For the treatment initiation model,
we used a logistic regression models including CD41/2m , current log viral load, gender, age,
injection drug use, month, days since last visit, indication of first visit, indication of second
visit, race, as discussed in Lok and Griner (2014). For Eξ2{H(k) | L¯m, A¯m = 0¯}, we used a
regression model adjusting for CD4m, CD4
3/4
m (k−m), CD43/4m age(k−m), CD43/4m race(k−m),
CD43/4m injdrug(k−m), whether there is a CD4 slope measure, CD4slopem(k−m)1/2, (6−m)+,
and (62 −m2)+ with a+ ≡ a × 1(a > 0). The model was motivated by (3). The inclusion
of CD4m, CD4
3/4
m (k −m), and CD43/4m age(k −m) was suggested from a stochastic model of
Y
(∞)
ik for each patient i over time k, {Y (∞)ik }1/4 = ai+ bk+γ1age+γ2agek+φWik+ ǫik, where
ai is a normal random effect, Wik is a Brownian motion process, ǫik is normal with mean
zero and constant variance, and ai, Wik, ǫik and age are independent (Taylor et al., 1994).
Other covariates were suggested in Taylor and Law (1998) and May et al. (2009).
Table 2 shows the results from fitting the optimal estimator of the null treatment effect
model, along with the goodness-of-fit tests directed at gender, age, and injection drug use.
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The p-values are all greater than 0 · 05. To avoid the multiple testing problem, we did not
consider other tests. The three tests were specified prior to the actual calculation. The results
show a benefit of combination antiretroviral treatment; for example, starting treatment at
the estimated date of infection would lead to an expected added improvement in CD4 counts
of 12ψˆ1 = 299 cells/mm
3 after a year of therapy. Delaying treatment initiation during acute
and early infection may diminish the CD4 count gain associated with one year treatment
(ψˆ2 < 0); however, this result is not statistically significant.
Table 2: The Acute Infection Early Disease Research Program data: the optimal estimator
fitting the null treatment effect model: point estimate (95% confidence intervals based on
the asymptotic normality result), along with goodness-of-fit statistics (Statistic), associated
degree of freedom (DF), and p-values (p-value) for the adequacy of the null model by testing
whether gender or injection drug use should be added into the model
ψˆ1(95% CI) ψˆ2 (95% CI)
24 · 88(21 · 61, 28 · 15) −0 · 48(−1 · 47, 0 · 52)
Goodness-of-fit test
Statistic DF p-value
Test directed at gender 0 · 99 1 0 · 32
Test directed at age 0 · 80 1 0 · 37
Test directed at injection drug use 2 · 93 1 0 · 09
8 Discussion
The applicability of the goodness-of-fit test procedure presented in this article is broad in
the causal inference literature. The testing procedure can also be developed for the tradi-
tional structural nested mean models (Robins, 1994) other than the time-dependent coarse
structural nested mean models considered in this article, and marginal structural models
(Robins, 2000), because both approaches yield overidentification of the parameters. For
the Inverse-Probability-of-Censoring-Weighting estimator of marginal structural models, un-
biased estimating equations are Pnq(V ){Y −µ(A¯, V )}w(A¯ | L¯) = 0, where Y is the outcome
at the end of study, A¯ is the treatment history, V is a subset of the baseline covariates,
µ(a¯, V ) ≡ E(Y a¯ | V ) is the marginal structural model, where Y a¯ is the counterfactual out-
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come had every individual received the treatment a¯, and w(A¯ | L¯) is the inverse of conditional
probability of receiving the actual treatment A¯ given L¯. These equations are unbiased for
most choices of q(V ), leading to a large class of unbiased estimating equations. The literature
of structural nested mean models and marginal structural models concentrates on estimation
and efficiency. Little attention has been given to goodness-of-fit tests. Our test procedure
for the treatment effect model can be developed in these contexts in the same manner.
Our goodness-of-fit test procedure can also deal with treatment of the form “initiate
treatment when the CD4 count first drops below x”. Especially in resource limited coun-
tries, and historically also in the US, initiation of combination antiretroviral treatment is
decided based on the CD4 count threshold. Orellana et al. (2010) proposed dynamic regime
marginal structural models and Lok et al. (2007) used structural nested mean models to
simultaneously compare dynamic treatment regimes of this form and estimate the optimal
one. Due to the popularity of these methods, the development of goodness-of-fit tests in
these settings will be useful for model diagnosis and protect causal estimates from biases
introduced by misspecification of the treatment effect model.
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